Zinaida Perić

Dr. Zinaida Perić


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2018 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
ZPZinaida Perić
Zinaida Perić
JWJonas Wilson
Jonas Wilson
NDNadira Duraković
Nadira Duraković
AOAlen Ostojic
Alen Ostojic
LDLana Desnica
Lana Desnica
RVRadovan Vrhovac
Radovan Vrhovac

1 January 2017 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
ACAline Clavert
Aline Clavert
ZPZinaida Perić
Zinaida Perić
EBEolia Brissot
Eolia Brissot
FMFlorent Malard
Florent Malard
TGThierry Guillaume
Thierry Guillaume
PCPatrice Chevallier
Patrice Chevallier
Late complications (LC) and quality of life (QOL) were analyzed in 110 adult patients who underwent reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) and were alive for more than 2 years after allo-SCT. Overall survival of these patients was 93% (95% confidence interval [CI], 88% to 99%) and 81% (95% CI, 71% to 94%) at 5 and 10 years, respectively. The primary cause of death was a recurrence of primary malignancy. With a median follow-up of 4.6 years (range, 2 to 12.1), chronic graft-versus-host disease (cGVHD) was the most prevalent late effect, with a cumulative incidence of 66% (95% CI, 57% to 74%) at 10 years. Cardiovascular complications were the most prevalent LC with a cumulative incidence of 47% (95% CI, 35% to 59%), followed by pulmonary complications with a cumulative incidence of 33% (95% CI, 21% to 46%) and renal impairment with a cumulative incidence of 34% (95% CI, 25% to 43%) at 10 years. Secondary malignancies occurred with a cumulative incidence of 11% (95% CI, 5% to 20%) at 10 years. In this series, 61 patients (55%) responded to QOL survey. With the use of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 and Functional Assessment of Cancer Therapy-Bone Marrow Transplant questionnaires, most of the patients reported good to excellent QOL and patients with cGVHD had significantly lower QOL than patients without cGVHD. In conclusion, QOL after RIC is comparable to that seen after myeloablative conditioning, while the natural history of LC after RIC appears to be different from that described in the standard myeloablative setting, warranting further research in this field.

1 February 2016 in Croatian Medical Journal
Verified
Journal Article
Open access
ZPZinaida Perić
Zinaida Perić
LDLana Desnica
Lana Desnica
NDNadira Duraković
Nadira Duraković
AOAlen Ostojić
Alen Ostojić
DPDražen Pulanić
Dražen Pulanić
DNDamir Nemet
Damir Nemet
To investigate the ability of two standard quality of life (QOL) questionnaires – The Short Form (36-item) Health Survey (SF-36) and The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ ...

1 March 2010
Verified
Journal Article
Closed access
NSNives Dzeko Skugor
Nives Dzeko Skugor
ZPZinaida Perić
Zinaida Perić
RVRadovan Vrhovac
Radovan Vrhovac
DRDelfa Radić-Kristo
Delfa Radić-Kristo
IKIka Kardum-Skelin
Ika Kardum-Skelin
BJBranimir Jaksić
Branimir Jaksić

11 November 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
ZSZrinka Sertić
Zrinka Sertić
MLMarko Lucijanic
Marko Lucijanic
SBSandra Bašić-Kinda
Sandra Bašić-Kinda
RSRanka Serventi Seiwerth
Ranka Serventi Seiwerth
VPVlatka Periša
Vlatka Periša
NDNadira Duraković
Nadira Duraković
Disease- and treatment-mediated immunodeficiency might render SARS-CoV-2 vaccines less effective in patients with hematologic diseases. We performed a prospective non-interventional study to evaluate humoral response after one and two doses of mRNA-1273, BNT162b2, or ChAdOx1 nCoV-19 vaccine in 118 patients with different malignant or non-malignant hematologic diseases from three Croatian treatment centers. An electrochemiluminescent assay was used to measure total anti-SARS-CoV-2 S-RBD antibody titers. After one vaccine dose, 20/66 (33%) achieved seropositivity with a median antibody titer of 6.1 U/mL. The response rate (58/90, 64.4%) and median antibody titer (>250 U/mL) were higher after two doses. Seropositivity varied with diagnosis (overall p < 0.001), with the lowest rates in lymphoma (34.6%) and chronic lymphocytic leukemia (52.5%). The overall response rate in chronic myeloproliferative neoplasms (CMPN) was 81.3% but reached 100% in chronic myeloid leukemia and other non-myelofibrosis CMPN. At univariable analysis, age > 67 years, non-Hodgkin’s lymphoma, active treatment, and anti-CD20 monoclonal antibody therapy increased the likelihood of no vaccine response, while hematopoietic stem cell recipients were more likely to respond. Age and anti-CD20 monoclonal antibody therapy remained associated with no response in a multivariable model. Patients with the hematologic disease have attenuated responses to SARS-CoV-2 vaccines, and significant variations in different disease subgroups warrant an individualized approach.

1 March 2010
Verified
Journal Article
Closed access
RVRadovan Vrhovac
Radovan Vrhovac
ZPZinaida Perić
Zinaida Perić
SJSilvana Jurenec
Silvana Jurenec
IKIka Kardum-Skelin
Ika Kardum-Skelin
BJBiljana Jelić-Puskarić
Biljana Jelić-Puskarić
BJBranimir Jaksić
Branimir Jaksić